Spring is the most common time of the year for people to experience seasonal allergy symptoms. As the weather gets warmer and plants start to bloom, trees and grasses release pollen into the air, ...

The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Wed, January 22, 2025 at 1:29 PM UTC ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...

Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...